Liquid perfluorochemical inhibits inducible nitric oxide synthase expression and nitric oxide formation in lipopolysaccharide-treated RAW 264.7 macrophages

Journal of Pharmacological Sciences

Volumn 111, Issue 2, 2009, Pages 147-154

  Chang, Li Ping ^a   Lai, Yuan Shu ^b   Wu, Chang Jer ^c   Chou, Tz Chong ^d  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b TAIPEI CITY HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN OCEAN UNIVERSITY   (Taiwan)

^d NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

Cytokine; Lipopolysaccharide; Macrophage; Nitric oxide; Perfluorocarbon

Indexed keywords

FLUOROCARBON; FLUOROCARBON 77; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; LIPOPOLYSACCHARIDE; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; MACROPHAGE; NONHUMAN; PROTEIN EXPRESSION; VAPOR PRESSURE;

EID: 70350492342     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.09043FP     Document Type: Article

References (36)

1. Hirschl RB, Tooley R, Parent AC, Johnson K, Barlett RH. Improvement of gas exchange, pulmonary function, and lung injury with partial liquid ventilation. Chest. 1995;108:500-508.
2. Hirschl RB, Tooley R, Parent AC, Johnson K, Barlett RH. Evaluation of gas exchange, pulmonary compliance, and lung injury during total and partial liquid ventilation in the acute respiratory distress syndrome. Crit Care Med. 1996;21:1270-1278.
3. Haeberle HA, Nesti F, Dieterich H-J, Gatalica Z, Garofalo RP. Perflubron reduces lung inflammation in respiratory syncytial virus infection by inhibiting chemokine expression and nuclear factor-κB activation. Am J Respir Crit Care Med. 2002;165: 1433-1438. (Pubitemid 34522949)
4. Jeng M-J, Kou YR, Sheu C-C, Hwang B. Effects of partial liquid ventilation with FC-77 on acute lung injury in newborn piglets. Pediatr Pulmonol. 2002;33:12-21. (Pubitemid 34031549)
5. Shaffer TH, Wolfson MR, Clark LC. Liquid ventilation. Pediatr Pulmonol. 1992;14:102-109.
6. Raghavendran K, Pryhuber GS, Chess PR, Davidson BA, Knight PR, Notter RH. Pharmacotherapy of acute lung injury and acute respiratory distress syndrome. Curr Med Chem. 2008;15:1911-1924.
7. Thomassen MJ, Buhrow LT, Wiedemann HP. Perflubron decreases inflammatory cytokine production by human alveolar macrophages. Crit Care Med. 1997;25:2045-2047. (Pubitemid 28007244)
8. Croce MA, Fabian TC, Patton JH Jr, Melton SM, Moore M, Trenthem LL. Partial liquid ventilation decreases the inflammatory response in the alveolar environment of trauma patients. J Trauma. 1998;45:273-280.
9. Smith TM, Steinhorn DM, Thusu K, Fuhrman BP, Dandona P. A liquid perfluorochemical decreases the in vitro production of reactive oxygen species by alveolar macrophages. Crit Care Med. 1995;23:1533-1539.
10. Rotta AT, Gunnarsson B, Hernan LJ, Fuhrman BP, Steinhorn DM. Partial liquid ventilation with perflubron attenuates in vivo oxidative damage to proteins and lipids. Crit Care Med. 2000;28:202-208. (Pubitemid 30091053)
11. Chang H, Kuo FC, Lai YS, Chou TC. Inhibition of inflammatory responses by FC-77, a perfluorochemical, in lipopolysaccharide-treated RAW 264.7 macrophages. Intensive Care Med. 2005;31:977-984. (Pubitemid 40941732)
12. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991;43: 109-142.
13. Vane JR, Mitchell JA, Appleton I, Tomlinson A, Bishop-Bailey D, Croxtall J, et al. Inducible isoforms of cyclooxygenase and nitric oxide synthase in inflammation. Proc Natl Acad Sci U S A. 1994;91:2046-2050. (Pubitemid 24092039)
14. Blantz RC, Munger K. Role of nitric oxide in inflammatory conditions. Nephron. 2002;90:373-378. (Pubitemid 34310099)
15. Chou TC, Li CY, Wu TM, Tang ST, Lee AR, Ding YA. Beneficial effect of HCL-31D in murine models of endotoxaemia. Naunyn Schmiedebergs Arch Pharmacol. 2001;364: 213-219.
16. MacMicking JD, Nathan C, Hom G, Chartrain N, Fletcher DS, Trumbauer M, et al. Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. Cell. 1995;81:641-650.
17. Fujii Y, Goldberg P, Hussain SNA. Contribution of macrophages to pulmonary nitric oxide production in septic shock. Am J Respir Crit Care Med. 1998;157:1645-1651. (Pubitemid 28242104)
18. 2, nitric oxide, and superoxide by macrophages. J Trauma. 1994;37:82-89.
19. Tsao L-T, Tsai P-S, Lin R-H, Huang L-J, Kuo S-C, Wang J-P. Inhibition of lipopolysaccharide-induced expression of inducible nitric oxide synthase by phenolic (3E)-4-(2-hydroxyphenyl) but-3-en-2-one in RAW 264.7 macrophages. Biochem Pharmacol. 2005;70:618-626. (Pubitemid 40978552)
20. Ahn KS, Noh EJ, Zhao HL, Jung SH, Kang SS, Kim YS. Inhibition of inducible nitric oxide synthase and cyclooxygenase II by Platycodon grandiflorum saponins via suppression of nuclear factor-κB activation in RAW 264.7 cells. Life Sci. 2005;76: 2315-2328. (Pubitemid 40313419)
21. Nathan C, Xie QW. Regulation of biosynthesis of nitric oxide. J Biol Chem. 1994; 269:13725-13728.
22. Wang P, Wu P, Siegel MI, Egan RW, Billah MM. IL-10 inhibits transcription of cytokine genes in human peripheral blood mononuclear cells. J Immunol. 1994;153:811-816. (Pubitemid 24206311)
23. Dokka S, Shi X, Leonard S, Wang L, Castranova V, Rojanasakul Y. Interleukin-10-mediated inhibition of free radical generation in macrophages. Am J Physiol. 2001;280:L1196-L1202. (Pubitemid 32553258)
24. Huang CJ, Stevens BR, Nielsen RB, Slovin PN, Fang X, Nelson DR, et al. Interleukin-10 inhibition of nitric oxide biosynthesis involves suppression of CAT-2 transcription. Nitric Oxide. 2002;6:79-84. (Pubitemid 34848268)
25. Dugas N, Palacios-Calender M, Dugas B, Riveros-Moreno V, Delfraissy JF, Kolb JP, et al. Regulation by endogenous interleukin-10 of the expression of nitric oxide synthase induced after ligation of CD23 in human macrophages. Cytokine. 1998;10:680-689. (Pubitemid 28457112)
26. Tak PP, Firestein GS. NF-kappaB. a key role in inflammatory diseases. J Clin Invest. 2001;170:7-11.
27. Sun Z, Andersson R. NF-kappa B activation and inhibition: a review. Shock. 2002;18:99-106.
28. Xie Q-W, Kashiwabara Y, Nathan C. Role of transcriptional factor NF-κB/Rel in induction of nitric oxide synthase. J Biol Chem. 1994;269:4705-4708. (Pubitemid 24239438)
29. Lundberg JO, Weitzberg E. NO generation from nitrite and its role in vascular control. Arterioscler Thromb Vasc Biol. 2005; 25:915-922.
30. Victor VM, Rocha M, Esplugues JV, De la Fuente M. Role of free radicals in sepsis: antioxidant therapy. Curr Pharm Des. 2005;11:3141-3158. (Pubitemid 41149930)
31. Kukreja RC, Hess ML. The oxygen free radical system: from equations through membraneprotein interactions to cardiovascular injury and protection. Cardiovasc Res. 1992;26:641-655.
32. Gloire G, Legrand-Poels S, Piette J. NF-kappaB activation by reactive oxygen species: fifteen years later. Biochem Pharmacol. 2006;30:1493-1505. (Pubitemid 44666727)
33. 6 glial cells and astrocytes. Free Radic Biol Med. 1998;24:39-48.
34. 2 and nitric oxide in inducible nitric oxide synthase expression in macrophages. Nitric Oxide. 2001;5:504-513.
35. Smith TM, Steinhorn DM, Thusu K, Fuhrman BP, Dandona P. A liquid perfluorochemical decreases the in vitro production of reactive oxygen species by alveolar macrophages. Crit Care Med. 1995;23:1533-1539.
36. Gause EM, Rowlands JR. Effects of fluorocarbon inhalants upon alveolar macrophages. Proc West Pharmacol Soc. 1976;19:373-380.